Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Establish the objective tumor response rate (CR + PR) following treatment with VELCADE plus Alimta or Alimta alone or VELCADE alone in subjects with locally advanced or metastatic NSCLC who have failed prior antineoplastic therapy for Stage IIIb/IV NSCLC.
Inclusion criteria
- non-small cell lung cancer